Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Current Assets (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Current Assets for 16 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 6.89% to $48.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.2 million through Dec 2025, up 6.89% year-over-year, with the annual reading at $48.2 million for FY2025, 6.89% up from the prior year.
  • Current Assets for Q4 2025 was $48.2 million at Harvard Bioscience, up from $43.8 million in the prior quarter.
  • The five-year high for Current Assets was $61.6 million in Q4 2021, with the low at $43.8 million in Q3 2025.
  • Average Current Assets over 5 years is $50.6 million, with a median of $49.9 million recorded in 2021.
  • The sharpest move saw Current Assets rose 27.95% in 2021, then fell 16.98% in 2022.
  • Over 5 years, Current Assets stood at $61.6 million in 2021, then dropped by 16.98% to $51.1 million in 2022, then decreased by 4.08% to $49.0 million in 2023, then dropped by 8.0% to $45.1 million in 2024, then increased by 6.89% to $48.2 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $48.2 million, $43.8 million, and $45.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.